PTEN anticorps (C-Term)

N° du produit ABIN6242539

Cet anticorps anti-PTEN est un anticorps Lapin Polyclonal détectant PTEN dans WB, IF et IHC (p). Adapté pour Humain. Ce Primary Antibody a été cité dans 1 publication.

Aperçu rapide pour PTEN anticorps (C-Term) (ABIN6242539)

Antigène: PTEN (Phosphatase and Tensin Homolog (PTEN))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PTEN est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB5083

Détail du produit anti-PTEN anticorps

Épitope: AA 264-295, C-Term

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogène: This PTEN antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 264-295 amino acids from the C-terminal region of human PTEN.

Isotype: Ig Fraction

Information d'application

Indications d'application: IF: 1:10~50. WB: 1:1000. IHC-P: 1:10~50

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Date de péremption: 6 months

Références pour anticorps anti-PTEN (ABIN6242539)

Agouni, Mody, Owen, Czopek, Zimmer, Bentires-Alj, Bence, Delibegović: "Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity- and pharmacologically induced endoplasmic reticulum stress." dans: The Biochemical journal, Vol. 438, Issue 2, pp. 369-78, (2011) (PubMed).

Détails sur PTEN

Antigène: PTEN (Phosphatase and Tensin Homolog (PTEN))

Autre désignation: PTEN

Sujet: PTEN, (phosphatase and tensin homolog deleted on chromosome 10), also known as MMAC1 (mutated in multiple advanced cancers 1), is a tumor suppressor implicated in a large number of human tumors. The PTEN phosphatase incorporates the catalytic motif (HCXXGXXRS/T) that is a signature of the protein tyrosine phosphatase family. Recombinant human PTEN is a dual phosphatase with ability to dephosphorylate both tyrosine and serine/threonine residues. PTEN functions primarily as a lipid phosphatase to regulate signal transduction pathways, with a primary target identified as phosphatidylinositol 3,4,5 trisphosphate. In addition, PTEN presents weak tyrosine phosphatase activity, which may downregulate signaling pathways involving focal adhesion kinase or Shc. PTEN negatively regulates activation of the serine/threonine kinase Akt/PKB by blocking its phosphorylation, thereby inhibiting the PI 3 kinase Akt signaling pathway, which is important for cell survival. In vivo, the majority of PTEN missense mutations detected in tumor specimens target the phosphatase domain and cause a loss in PTEN phosphatase activity. Mutations in PTEN are associated with several common cancers including prostate, brain and breast cancer, and with Cowden's disease, an autosomal dominant disorder conferring susceptibility to benign and malignant tumors. Germline mutations of PTEN are also linked Lhermitte-Duclos disease and Bannayan-Zonana syndrome. Mutations of PTEN occur in 60 to 80 % of prostate cancers. PTEN is also essential for embryonic development.

Poids moléculaire: 47166

NCBI Accession: NP_000305

UniProt: P60484

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Inositol Metabolic Process, Synaptic Membrane, Regulation of Cell Size, Autophagy, Platelet-derived growth Factor Receptor Signaling, Signaling of Hepatocyte Growth Factor Receptor, BCR Signaling